Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evoq RemediesBOM:543500 59 EPS without NRI is ₹-0.10 as of Mar. 2026. GuruFocus rates BOM:543500 with a GF Score™ of 59/100 and a GF Value™ of ₹12.88 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 101 Medical Distribution companies, Evoq Remedies ranks worse than 990098.02% on this metric.
Evoq Remedies's earnings per share without non-recurring items for the
six
months ended in Mar. 2026 was ₹-0.12.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-0.10.
During the past 12 months, Evoq Remedies's average earnings per share (NRI) Growth Rate was -385.70% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Evoq Remedies's EPS without NRI or its related term are showing as below:
During the past 8 years, Evoq Remedies's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 344.00% per year. The lowest was -63.20% per year. And the median was -63.00% per year.
BOM:543500's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Distribution industry.
Industry Median: 2.6 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Evoq Remedies's EPS (Diluted) for the
six
months ended in Mar. 2026 was ₹-0.12.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-0.10.
Evoq Remedies's EPS (Basic) for the
six
months ended in Mar. 2026 was ₹-0.12.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-0.10.
Evoq Remedies (BOM:543500) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Evoq Remedies EPS without NRI Related Terms
Evoq Remedies EPS without NRI Historical Data
* Premium members only.
The historical data trend for Evoq Remedies's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543500 vs MCK, COR, CAH: EPS without NRI Comparison
For the Medical Distribution subindustry, Evoq Remedies's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evoq Remedies PE Ratio without NRI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Evoq Remedies's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Evoq Remedies's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹-0.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evoq Remedies (BOM:543500) has a EPS without NRI of ₹-0.10 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Evoq Remedies and its competitors. According to the industry distribution chart, Evoq Remedies ranks #999999 out of 101 companies in the Medical Distribution industry.
Is Evoq Remedies' EPS without NRI too high?
Evoq Remedies' current EPS without NRI is ₹-0.10. Based on the distribution chart, Evoq Remedies ranks #999999 out of 101 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Evoq Remedies has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evoq Remedies' EPS without NRI compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Evoq Remedies ranks #999999 out of 101 companies for EPS without NRI. This places Evoq Remedies in the lower half of its industry. The industry median EPS without NRI is 2.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Distribution company?
The median EPS without NRI among Medical Distribution companies is 2.60, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Evoq Remedies and its competitors. For the Medical Distribution industry, the median EPS without NRI is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evoq Remedies's current EPS without NRI is ₹-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evoq Remedies stock overvalued right now?
Based on GuruFocus' analysis, Evoq Remedies (BOM:543500) is currently considered Possible Value Trap. The stock's GF Value™ is ₹12.88, compared to a current price of ₹1.80 — trading 86% below its estimated fair value. The current EPS without NRI is ₹-0.10. Evoq Remedies' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Evoq Remedies (BOM:543500), the current EPS without NRI is ₹-0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evoq Remedies (BOM:543500) Overvalued in 2026?
Based on GuruFocus' analysis, Evoq Remedies stock appears to be undervalued.
The current stock price of ₹1.80 is trading 86% below its estimated GF Value™ of ₹12.88.
GuruFocus considers Evoq Remedies to be Possible Value Trap.
Key valuation signals for BOM:543500:
EPS without NRI: ₹-0.10
GF Value™: ₹12.88 vs. price of ₹1.80 (86% below fair value)
No single metric tells the full story. See the BOM:543500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evoq Remedies Ltd is engaged in the pharmaceutical business involving marketing, trading, and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, calcium, multivitamins, injections, and others. It operates in a single segment that is Pharmaceutical Trading.
59GF Score
Get the complete analysis for BOM:543500
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543500 has been successfully added to your 
